Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339547 | 1.00 | NOTUM (0.44) | NOTUMS1PR5FFAR1F10NPC1 | |
| SCHEMBL26171399 | 0.93 | S1PR5 (0.46) | S1PR5 | |
| SCHEMBL28899818 | 0.91 | LTA4H (0.39) | S1PR5F10 | |
| SCHEMBL25957189 | 0.91 | LTA4H (0.39) | S1PR5F10 | |
| SCHEMBL25952841 | 0.91 | NOTUM (0.44) | NOTUMS1PR5FFAR1F10 | |
| SCHEMBL31155491 | 0.89 | CCNT1 (0.37) | NOTUMS1PR5F10 | |
| SCHEMBL30511792 | 0.88 | MYC (0.38) | NPC1RAB9A | |
| SCHEMBL31312913 | 0.86 | LRRK2 (0.37) | S1PR5 | |
| SCHEMBL26003250 | 0.86 | LRRK2 (0.37) | S1PR5 | |
| SCHEMBL24207632 | 0.86 | ACACB (0.37) | S1PR5F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024217481-A1 | EGFR DEGRADING AGENT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-17 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-04-25 | — | — | US | disclosed |
| CN-117616021-A | (R) -glutarimide CRBN ligands and methods of use | 百济神州有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117222637-A | EGFR degrading agents and related methods of use | 百济神州有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| CN-116323580-A | Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115260237-A | EGFR-degrading agents and related methods of use | 百济神州(北京)生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | NOTUM 3308/4885S1PR5 4304/4885FFAR1 4015/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | NOTUM 3236/4885S1PR5 3893/4885FFAR1 4354/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | NOTUM 3308/4885S1PR5 4304/4885FFAR1 4015/4885 |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | NOTUM 3497/4885S1PR5 4145/4885FFAR1 3711/4885 |
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | EGFR, ERBB2, ERBB3 | NOTUM 3508/4885S1PR5 4268/4885FFAR1 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.